Advanced Search

Molecular Pharmacology Evaluations

To view Evaluated Articles, you must have an active subscription (or trial) and be signed in.
If you have an active subscription (or trial), please sign in. If your access has expired, you can subscribe at $9.95 per month. If you think you should be able to access this content, please contact us.

Sign in | Free Trial | Subscribe | Recommend to Library

New to F1000? See the Top Rated article below for a free preview of one of our Evaluated Articles.

SECTION HEADS

  • Photo of Gary Johnson

    Gary Johnson

    Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

  • Photo of Terry Kenakin

    Terry Kenakin

    Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill,, North Carolina, USA

  • Photo of Graeme Milligan

    Graeme Milligan

    Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, UK

Section Topics

  • » Angiotensin/ blood pressure regulation
  • » Animal models
  • » Class C GPCRs, glutamate function, neurobiology
  • » G proteins
  • » Kinases
  • » Ligand binding studies/drug identification/asthma
  • » MAP kinase cascades, signaling & cancer
  • » Melatonin/ sleep regulation
  • » Modeling & 3D Structure
  • » Phosphatases
  • » Receptor phosphorylation/apoptosis
  • » Receptor/G protein interactions

LATEST EVALUATION

This paper shows that NMDA receptor-mediated long-term potentiation (LTP) in the bed nucleus of the stria terminalis (BNST), a brain area important in drug addiction, depends upon the GluN2B NMDA receptor subunit, and that chronic...

Robert Peoples, Marquette University, USA. F1000 Pharmacology & Drug Discovery

6 Recommended

TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]

10
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Bollag G, Hirth P, Tsai J, Zhang J, ..., Flaherty KT, Xu X, Nathanson KL, Nolop K. Nature. 2010 Sep 30; 467(7315):596-9

3 Evaluations, most recent by

Miles Congreve, Heptares Therapeutics Ltd, UK. F1000 Pharmacology & Drug Discovery

  • New Finding
  • Confirmation
  • Technical Advance
  • Clinical Trial

INDIVIDUALS

Get instant access to evaluations from over 10,000 experts in biology and medicine by taking a free trial or an individual subscription.

Get a FREE Trial Subscribe for $9.95 per month

Already have a subscription? Sign in for instant access. If you are signed in but are not able to view content, your access has expired. Please take out a subscription or recommend F1000 to your librarian.

RECOMMENDATIONS

Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.

Recommend to your Librarian

LIBRARIANS & INFORMATION MANAGERS

Get an extended free trial supporting clinicians and researchers at your academic or corporate institution.

Request an Institutional Trial

FREE ACCESS

Your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.

Faculty of 1000